Why Shares of ImmunoGen Inc. Shot Up Today
ImmunoGen (NASDAQ: IMGN) ended Friday up 14% after reporting second-quarter earnings earlier in the day. Of course, it wasn't the cancer-focused biotech's earnings that caused shares to jump by double digits, since the company doesn't currently sell any drugs.
For the record, revenue came in at $39 million, most of which was from a previously disclosed $30 million payment from Sanofi (NYSE: SNY). The companies amended their agreement over isatuximab and three other earlier-stage drug candidates so ImmunoGen could get cash now in exchange for royalties later.
So while ImmunoGen's $8.9 million loss for the second quarter might at first glance appear to be significantly less than the $45.9 million it lost in Q2 2016, it wasn't not that different if you factor out the payment from Sanofi.
Source: Fool.com
Sanofi S.A. ADR Stock
Our community is currently high on Sanofi S.A. ADR with 4 Buy predictions and 0 Sell predictions.
With a target price of 49 € there is a positive potential of 29.63% for Sanofi S.A. ADR compared to the current price of 37.8 €.
